バイオ医薬品CMO・CRO市場：供給元、サービスタイプ、製品タイプ、事業規模、治療用途別-2025-2030年世界予測

バイオ医薬品CMO・CRO市場の2023年の市場規模は813億2,000万米ドルで、2024年には956億5,000万米ドルに達すると予測され、2030年にはCAGR 18.10%で2,606億5,000万米ドルに成長すると予測されています。

バイオ医薬品の医薬品開発業務受託機関（CMO）と研究開発業務受託機関（CRO）市場は、コストと生産能力の制約を緩和しながら医薬品イノベーションを推進し、医薬品開発と製造の連続体において不可欠な存在となっています。CMOは前臨床開発から商業生産までの製造サービスを提供し、CROは専門的な知識と分析ツールによって新薬開発を加速させる研究サービスを提供します。厳しい規制環境の中、製薬会社が市場投入までの時間を短縮しようと努力する中で、この共生関係はますます必要となっています。応用範囲には、生物製剤、バイオシミラー、低分子化合物、個別化医療が含まれ、最終用途産業は治療薬からワクチンまで多岐にわたる。主な成長要因としては、慢性疾患の蔓延、生物製剤とバイオシミラーの進歩、政府による優遇措置、運用リスクとコストを下げつつ市場競争力を維持しようとする製薬企業によるアウトソーシング傾向などが挙げられます。最新のビジネスチャンスは、ニッチなスキルセットと能力を求めてCMO/CROとの提携を求めるバイオテクノロジー新興企業の急増と、新興市場全体での臨床試験需要の高まりにあります。とはいえ、市場は複雑な規制状況、知的財産権、品質保証の問題などの課題に直面しており、これがしばしばシームレスな成長と拡張性を制約しています。さらに、市場は高い競合情勢と熟練労働者の必要性からも影響を受けており、これが事業運営を複雑にしています。人工知能や機械学習を利用したプロセスの最適化、医薬品開発と製造プロセスにおけるデータ主導の意思決定強化、継続的製造による効率化などの分野では、技術革新と研究の機会が豊富にあります。企業は、堅牢なQuality by Design（QbD）フレームワークやデータ分析に投資してコンプライアンスを強化し、タイムラインを短縮することで利益を得ることができます。市場の特徴は、急速な技術進歩、競合他社との競争、規制当局の監視であり、持続的な成長にはビジネスの俊敏性と適応性が不可欠です。

市場力学：急速に進化するバイオ医薬品CMO・CRO市場の主要市場インサイトを公開

バイオ医薬品CMO・CRO市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 製薬・バイオテクノロジー分野でのアウトソーシングニーズの高まり
  • 高分子治療薬に対する潜在的需要
  • バイオ医薬品セクターにおける継続的な研究開発活動
• 市場抑制要因
  • 外注先の減少や競合の減少に関連する問題
• 市場機会
  • バイオテクノロジー分野における先端技術の浸透
  • 標的治療のための細胞・遺伝子治療の出現
• 市場の課題
  • CMOとCROの説明責任と品質管理に関する懸念

ポーターの5つの力：バイオ医薬品CMO・CRO市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：バイオ医薬品CMO・CRO市場における外部からの影響の把握

外部マクロ環境要因は、バイオ医薬品CMO・CRO市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析バイオ医薬品CMO・CRO市場における競合情勢の把握

バイオ医薬品CMO・CRO市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスバイオ医薬品CMO・CRO市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、バイオ医薬品CMO・CRO市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨バイオ医薬品CMO・CRO市場における成功への道筋を描く

バイオ医薬品CMO・CRO市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 製薬・バイオテクノロジー分野でアウトソーシングサービスのニーズが増加
    • 高分子治療薬の潜在的需要
    • バイオ医薬品分野における進行中の研究開発活動
  • 抑制要因
    • アウトソーシングサプライヤーの減少と競合の減少に関連する問題
  • 機会
    • バイオテクノロジー分野における先端技術の浸透
    • 標的治療のための細胞・遺伝子治療の出現
  • 課題
    • CMOとCROの説明責任と品質管理に関する懸念
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 バイオ医薬品CMO・CRO市場：ソース別

• 哺乳類
• 非哺乳類

第7章 バイオ医薬品CMO・CRO市場：サービスタイプ別

• 契約製造
• 委託調査

第8章 バイオ医薬品CMO・CRO市場：製品別

• 生物学的製剤
• バイオシミラー

第9章 バイオ医薬品CMO・CRO市場事業規模別

• 臨床
• 商業用

第10章 バイオ医薬品CMO・CRO市場治療アプリケーション

• 心血管疾患
• 感染症
• 神経学
• 腫瘍学
• 眼科
• 呼吸器疾患

第11章 南北アメリカのバイオ医薬品CMO・CRO市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域のバイオ医薬品CMO・CRO市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカのバイオ医薬品CMO・CRO市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie, Inc.
• arexel International Corporation
• Baxter International Inc.
• Boehringer Ingelheim Biopharmaceuticals GmbH
• Boehringer Ingelheim GmbH
• Catalent, Inc.
• Charles River Laboratories International, Inc.
• Eurofins Scientific Limited
• FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
• ICON Plc
• KBI Biopharma, Inc.
• KEMWELL BIOPHARMA PRIVATE LIMITED
• Laboratory Corporation of America Holdings
• Lonza Group AG
• NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC
• Patheon Inc.
• Rentschler Biopharma SE
• Sterling Pharma Solutions

LIST OF FIGURES

• FIGURE 1. BIOPHARMACEUTICAL CMO & CRO MARKET RESEARCH PROCESS
• FIGURE 2. BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. BIOPHARMACEUTICAL CMO & CRO MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. BIOPHARMACEUTICAL CMO & CRO MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BIOPHARMACEUTICAL CMO & CRO MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. BIOPHARMACEUTICAL CMO & CRO MARKET DYNAMICS
• TABLE 7. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NON-MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CONTRACT MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CONTRACT RESEARCH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESPIRATORY DISORDER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 42. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 43. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 44. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 45. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 46. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 58. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 64. AUSTRALIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 69. CHINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 70. CHINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 71. CHINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 72. CHINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 73. CHINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 74. INDIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 75. INDIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 76. INDIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 77. INDIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 78. INDIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 79. INDONESIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 80. INDONESIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 84. JAPAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 85. JAPAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 89. MALAYSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 90. MALAYSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 94. PHILIPPINES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 95. PHILIPPINES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 99. SINGAPORE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 100. SINGAPORE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 104. SOUTH KOREA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 105. SOUTH KOREA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 109. TAIWAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 110. TAIWAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 114. THAILAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 115. THAILAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 119. VIETNAM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 120. VIETNAM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 124. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 125. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 130. DENMARK BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 131. DENMARK BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 135. EGYPT BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 136. EGYPT BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 140. FINLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 141. FINLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 145. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 146. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 150. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 151. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 155. ISRAEL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 156. ISRAEL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 160. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 161. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 162. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 163. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 164. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 165. NETHERLANDS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 166. NETHERLANDS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 170. NIGERIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 171. NIGERIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 175. NORWAY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 176. NORWAY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 180. POLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 181. POLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 182. POLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 183. POLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 184. POLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 185. QATAR BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 186. QATAR BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 187. QATAR BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 188. QATAR BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 189. QATAR BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 190. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 191. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 195. SAUDI ARABIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 196. SAUDI ARABIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 200. SOUTH AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 205. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 206. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 210. SWEDEN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 211. SWEDEN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 215. SWITZERLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 216. SWITZERLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 220. TURKEY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 221. TURKEY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 225. UNITED ARAB EMIRATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 226. UNITED ARAB EMIRATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 230. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 231. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 235. BIOPHARMACEUTICAL CMO & CRO MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 236. BIOPHARMACEUTICAL CMO & CRO MARKET, FPNV POSITIONING MATRIX, 2023

The Biopharmaceutical CMO & CRO Market was valued at USD 81.32 billion in 2023, expected to reach USD 95.65 billion in 2024, and is projected to grow at a CAGR of 18.10%, to USD 260.65 billion by 2030.

The biopharmaceutical Contract Manufacturing Organization (CMO) and Contract Research Organization (CRO) markets have become essential in the drug development and manufacturing continuum, propelling pharmaceutical innovations while mitigating costs and capacity constraints. CMOs provide manufacturing services that range from pre-clinical development to commercial production, while CROs offer research services to aid clients in accelerating the development of new drugs through specialized knowledge and analytical tools. This symbiotic relationship is increasingly necessary as pharmaceutical companies strive to expedite time-to-market amidst stringent regulatory environments. The application scope includes biologics, biosimilars, small molecules, and personalized medicine, with end-use industries spanning therapeutics to vaccines. Key growth influencers include the rising prevalence of chronic diseases, advancements in biologics and biosimilars, governmental incentives, and the outsourcing trend by pharmaceutical companies eager to retain market competitiveness while lowering operational risks and costs. The latest opportunities lie in the surge of biotechnology startups seeking partnerships with CMOs/CROs for niche skill sets and capabilities, and the growing demand for clinical trials across emerging markets. Nevertheless, the market grapples with challenges such as complex regulatory landscapes, intellectual property concerns, and quality assurance issues, which often constrain seamless growth and scalability. Additionally, the market is impacted by high competition and the need for skilled labor, which complicate the operational landscapes. Innovation and research opportunities abound in areas like process optimization using artificial intelligence and machine learning, enhancing data-driven decision-making in drug development and manufacturing processes, and increasing efficiency through continuous manufacturing. Companies can benefit from investing in robust Quality by Design (QbD) frameworks and data analytics to enhance compliance and accelerate timelines. The market is characterized by rapid technological advancements, competitive collaboration, and regulatory scrutiny, making business agility and adaptability crucial for sustained growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biopharmaceutical CMO & CRO Market

The Biopharmaceutical CMO & CRO Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising need for outsourced service in pharmaceutical and biotechnology sector
  • Potential demand for macromolecular therapeutics
  • Ongoing research and development activities in biopharmaceutical sector
• Market Restraints
  • Issues pertinent to fewer outsource suppliers and less competition
• Market Opportunities
  • Penetration of advanced technology in the biotechnology field
  • Emergence of Cell and Gene Therapies for Targeted Treatment
• Market Challenges
  • Concern associated with accountability and quality control of CMO and CRO

Porter's Five Forces: A Strategic Tool for Navigating the Biopharmaceutical CMO & CRO Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biopharmaceutical CMO & CRO Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biopharmaceutical CMO & CRO Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biopharmaceutical CMO & CRO Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biopharmaceutical CMO & CRO Market

A detailed market share analysis in the Biopharmaceutical CMO & CRO Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biopharmaceutical CMO & CRO Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biopharmaceutical CMO & CRO Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Biopharmaceutical CMO & CRO Market

A strategic analysis of the Biopharmaceutical CMO & CRO Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biopharmaceutical CMO & CRO Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., arexel International Corporation, Baxter International Inc., Boehringer Ingelheim Biopharmaceuticals GmbH, Boehringer Ingelheim GmbH, Catalent, Inc., Charles River Laboratories International, Inc., Eurofins Scientific Limited, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., ICON Plc, KBI Biopharma, Inc., KEMWELL BIOPHARMA PRIVATE LIMITED, Laboratory Corporation of America Holdings, Lonza Group AG, NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC, Patheon Inc., Rentschler Biopharma SE, and Sterling Pharma Solutions.

Market Segmentation & Coverage

This research report categorizes the Biopharmaceutical CMO & CRO Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Source, market is studied across Mammalian and Non-Mammalian.
• Based on Service Type, market is studied across Contract Manufacturing and Contract Research.
• Based on Product, market is studied across Biologics and Biosimilars.
• Based on Scale of Operation, market is studied across Clinical and Commercial.
• Based on Therapeutic Applications, market is studied across Cardiovascular Diseases, Infectious Disease, Neurology, Oncology, Ophthalmology, and Respiratory Disorder.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising need for outsourced service in pharmaceutical and biotechnology sector
    • 5.1.1.2. Potential demand for macromolecular therapeutics
    • 5.1.1.3. Ongoing research and development activities in biopharmaceutical sector
  • 5.1.2. Restraints
    • 5.1.2.1. Issues pertinent to fewer outsource suppliers and less competition
  • 5.1.3. Opportunities
    • 5.1.3.1. Penetration of advanced technology in the biotechnology field
    • 5.1.3.2. Emergence of Cell and Gene Therapies for Targeted Treatment
  • 5.1.4. Challenges
    • 5.1.4.1. Concern associated with accountability and quality control of CMO and CRO
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Biopharmaceutical CMO & CRO Market, by Source

• 6.1. Introduction
• 6.2. Mammalian
• 6.3. Non-Mammalian

7. Biopharmaceutical CMO & CRO Market, by Service Type

• 7.1. Introduction
• 7.2. Contract Manufacturing
• 7.3. Contract Research

8. Biopharmaceutical CMO & CRO Market, by Product

• 8.1. Introduction
• 8.2. Biologics
• 8.3. Biosimilars

9. Biopharmaceutical CMO & CRO Market, by Scale of Operation

• 9.1. Introduction
• 9.2. Clinical
• 9.3. Commercial

10. Biopharmaceutical CMO & CRO Market, by Therapeutic Applications

• 10.1. Introduction
• 10.2. Cardiovascular Diseases
• 10.3. Infectious Disease
• 10.4. Neurology
• 10.5. Oncology
• 10.6. Ophthalmology
• 10.7. Respiratory Disorder

11. Americas Biopharmaceutical CMO & CRO Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Biopharmaceutical CMO & CRO Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Biopharmaceutical CMO & CRO Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie, Inc.
• 2. arexel International Corporation
• 3. Baxter International Inc.
• 4. Boehringer Ingelheim Biopharmaceuticals GmbH
• 5. Boehringer Ingelheim GmbH
• 6. Catalent, Inc.
• 7. Charles River Laboratories International, Inc.
• 8. Eurofins Scientific Limited
• 9. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
• 10. ICON Plc
• 11. KBI Biopharma, Inc.
• 12. KEMWELL BIOPHARMA PRIVATE LIMITED
• 13. Laboratory Corporation of America Holdings
• 14. Lonza Group AG
• 15. NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC
• 16. Patheon Inc.
• 17. Rentschler Biopharma SE
• 18. Sterling Pharma Solutions